Daily Bio News Summary — 2026-07-25: Tensions across FDA panels, oncology approvals, and the Novo-Lilly ad war escalates

Top clusters

FDA advisory activity (3 articles, 2026-07-24 to 2026-07-25). An FDA panel narrowly rejected compounding of one peptide (epitalon) while backing two others (BPC-157, GHK-Cu) on the first day of a two-day meeting (STAT News, 2026-07-24). On the same day, Amgen submitted new analyses to the FDA in a bid to retain marketing authorization for Tavneos (Endpoints News, 2026-07-25). Bristol-Myers Squibb’s papaverine recall (via American Regent, PR Newswire FDA, 2026-07-24) rounds out the FDA-side activity.

Oncology approvals and pipeline discipline (3 articles). GSK’s Jideytro (belantamab) regimen won FDA accelerated approval for ROS1-positive lung cancer, validating the company’s $10.6B acquisition earlier this year (BioPharma Dive, 2026-07-24). Ipsen’s Bylvay (odevixibat) failed a Phase 3 trial in biliary atresia — the latest setback for the Albireo portfolio acquired in 2021 (Endpoints News, 2026-07-25). Novartis discontinued a mid-stage radioligand therapy program as Pluvicto continues to exceed sales expectations (BioSpace, 2026-07-22).

Novo-Lilly ad war (2 articles, 2026-07-24). Novo Nordisk escalated its false-advertising lawsuit against Eli Lilly, seeking a preliminary injunction to halt comparative ads (Fierce Pharma, 2026-07-24). The same day, BioPharma Dive covered the broader litigation pattern alongside J&J’s multiple-myeloma dominance story (BioPharma Dive, 2026-07-24).

Venus Medtech enrollment milestone (3 articles, 2026-07-23). Three trilingual press releases from Venus Medtech (Spanish, German, French) announced the completion of patient enrollment for the Venus Powerx TAVR pivotal Chinese trial (PR Newswire FDA, 2026-07-23). All three are distinct language-localized versions of the same corporate announcement.

OTC and regulatory wins (2 articles). The FDA approved Tylenol with Naproxen, the first OTC fixed-dose combination of acetaminophen 650 mg and naproxen sodium 220 mg (PR Newswire FDA, 2026-07-24). Lundbeck received FDA Fast Track designation for Lu AH69593, an investigational orexin-2 receptor agonist for narcolepsy (PR Newswire FDA, 2026-07-23).

Anthropic + Novartis CEO at the Endpoints event (1 article, 2026-07-25). Anthropic’s life sciences strategy was a major topic at the Endpoints News event, alongside Novartis CEO Vas Narasimhan on China deal-making (Endpoints News, 2026-07-25).

Metabolic and rare disease (2 articles). Eli Lilly’s triple-agonist retatrutide achieved 22% weight loss in its latest readout, but cardiovascular risk data fell short of analyst expectations (Fierce Biotech, 2026-07-23). A STAT podcast covers a father’s mission to fight for his daughter’s rare disease, alongside allegations around telehealth GLP-1 prescribing (STAT News, 2026-07-23).

Public health and policy (3 articles). U.S. measles cases in 2026 have already surpassed the entire 2025 total, with national vaccination rates falling below the herd immunity threshold (STAT News, 2026-07-24). House lawmakers are rallying behind a trade probe of U.S. biotech firms’ exposure to Chinese sequencing and genomics supply chains (Endpoints News, 2026-07-21). A STAT News series finale examines alcohol as the deadliest drug and surveys policy solutions (STAT News, 2026-07-14).

What this batch is NOT telling us

The 30-day window from 2026-06-25 through 2026-07-25 closes with a heavy FDA + oncology + oncology-supply-chain skew. Notable absences:

• No AI-bio clinical readouts. The Anthropic / Endpoints event coverage is a strategy story, not a clinical one. No AI-designed molecule made it through Phase 1 this week.
• No IPOs. The Scribe Therapeutics IPO that YESTERDAY’s run captured (2026-07-23) is already in the news folder from the previous run; no new IPOs today.
• No M&A beyond the Novo-Lilly ad war. The week’s deal volume is light.
• No PDUFA decisions. Three regulatory developments (Amgen-Tavneos, FDA peptide panel, GSK lung cancer) but no Clean PDUFA-action headlines.
• Fierce Biotech is missing from this batch. Its tab died during the harvest (Camofox memory pressure), so biotech-specific coverage is under-represented. Yesterday’s run captured ~5 FB articles; today has 0.

Reading order

If you have 10 minutes for today’s harvest, the highest-signal items are:

1. GSK lung cancer drug gets speedy approval (BioPharma Dive, 2026-07-24) — the $10.6B bet validated.
2. Amgen shares new analysis with FDA in bid to keep Tavneos on the market (Endpoints News, 2026-07-25) — regulatory stakes are high.
3. Novo escalates Lilly ad suit (Fierce Pharma, 2026-07-24) — the GLP-1 ad wars are now in court.
4. Ipsen’s Bylvay fails key trial in children with rare liver disease (Endpoints News, 2026-07-25) — pipeline setback.
5. House lawmakers rally behind trade probe of China biotech market (Endpoints News, 2026-07-21) — policy backdrop.

How to read the underlying articles

All 19 source files are in src/content/news/. Each one has sourceUrl, sourceName, and pubDate fields; click through to the original outlet for the full text. For company-specific articles, the companyId field links to the matching profile in src/content/companies/.

Full list of 19 items

1. Amgen shares new analysis with FDA in bid to keep Tavneos on the market — Endpoints News, 2026-07-25
2. Ipsen’s Bylvay fails key trial in children with rare liver disease — Endpoints News, 2026-07-25
3. Anthropic’s life science plans; Novartis CEO on China deals; and more from the Endpoints event — Endpoints News, 2026-07-25
4. FDA advisory panel narrowly rejects compounding of one peptide, backs two others — STAT News, 2026-07-24
5. There are already more U.S. measles cases this year than in all of 2025 — STAT News, 2026-07-24
6. American Regent Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection — PR Newswire FDA, 2026-07-24
7. FDA Approves TYLENOL with Naproxen — PR Newswire FDA, 2026-07-24
8. Novo escalates Lilly ad suit, plans bid to halt comparative ads — Fierce Pharma, 2026-07-24
9. Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma — BioPharma Dive, 2026-07-24
10. GSK lung cancer drug gets speedy approval following $10.6B deal — BioPharma Dive, 2026-07-24
11. A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing — STAT News, 2026-07-23
12. Lundbeck receives FDA Fast Track designation for Lu AH69593 — PR Newswire FDA, 2026-07-23
13. Venus Medtech anuncia la finalización del reclutamiento de pacientes para el ensayo clínico de Venus Powerx — PR Newswire FDA, 2026-07-23
14. Venus Medtech gibt den Abschluss der Patientenrekrutierung für die entscheidende chinesische Studie zu Venus Powerx bekannt — PR Newswire FDA, 2026-07-23
15. Venus Medtech annonce la fin du recrutement des patients dans le cadre de l’essai clinique décisif mené en Chine sur le Venus Powerx — PR Newswire FDA, 2026-07-23
16. Lilly triple-G drug hits 22% weight loss, cardio impact unclear — Fierce Biotech, 2026-07-23
17. Novartis scraps mid-stage radiopharma asset as Pluvicto soars — BioSpace, 2026-07-22
18. House lawmakers rally behind trade probe of China biotech market — Endpoints News, 2026-07-21
19. Alcohol Health Issues: Deadliest Drug Series Final Installment Solutions — STAT News, 2026-07-14